MX2019009861A - Composiciones farmaceuticas de un derivado de acido biliar y microbioma y usos de las mismas. - Google Patents

Composiciones farmaceuticas de un derivado de acido biliar y microbioma y usos de las mismas.

Info

Publication number
MX2019009861A
MX2019009861A MX2019009861A MX2019009861A MX2019009861A MX 2019009861 A MX2019009861 A MX 2019009861A MX 2019009861 A MX2019009861 A MX 2019009861A MX 2019009861 A MX2019009861 A MX 2019009861A MX 2019009861 A MX2019009861 A MX 2019009861A
Authority
MX
Mexico
Prior art keywords
pharmaceutical compositions
microbiome
acid derivative
bile acid
preparing
Prior art date
Application number
MX2019009861A
Other languages
English (en)
Inventor
Luciano Adorini
Gary D Wu
Hongzhe Lee
Farah Babakhani
Original Assignee
Intercept Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intercept Pharmaceuticals Inc filed Critical Intercept Pharmaceuticals Inc
Publication of MX2019009861A publication Critical patent/MX2019009861A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La solicitud se refiere a composiciones farmacéuticas que comprenden un compuesto de fórmula I y una o más especies de microbioma intestinal, y a métodos de preparación y uso de las mismas.
MX2019009861A 2017-02-23 2018-02-23 Composiciones farmaceuticas de un derivado de acido biliar y microbioma y usos de las mismas. MX2019009861A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762462658P 2017-02-23 2017-02-23
PCT/US2018/019451 WO2018156916A2 (en) 2017-02-23 2018-02-23 Pharmaceutical compositions of a bile acid derivative and microbiome and uses thereof

Publications (1)

Publication Number Publication Date
MX2019009861A true MX2019009861A (es) 2020-07-14

Family

ID=63254469

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019009861A MX2019009861A (es) 2017-02-23 2018-02-23 Composiciones farmaceuticas de un derivado de acido biliar y microbioma y usos de las mismas.

Country Status (12)

Country Link
US (1) US20200164005A1 (es)
EP (1) EP3585405A4 (es)
JP (1) JP2020509001A (es)
KR (1) KR20190117687A (es)
CN (1) CN110461337A (es)
AU (1) AU2018225255A1 (es)
BR (1) BR112019017417A2 (es)
CA (1) CA3053935A1 (es)
IL (1) IL268760A (es)
MX (1) MX2019009861A (es)
SG (1) SG11201907742YA (es)
WO (1) WO2018156916A2 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019205296B2 (en) * 2018-01-05 2021-12-23 Nubiyota Llc Compositions comprising co-selected microbiota and methods for use thereof
WO2019191649A1 (en) * 2018-03-29 2019-10-03 Freenome Holdings, Inc. Methods and systems for analyzing microbiota
ES2763350B2 (es) * 2018-11-28 2020-10-13 Consejo Superior Investigacion Cepa de christensenella minuta y uso de la misma
US11980645B2 (en) * 2019-01-22 2024-05-14 The Regents Of The University Of California Bile acids and use in disease treatment
US20220096495A1 (en) * 2019-02-04 2022-03-31 Intercept Pharmaceuticals, Inc. Treatment and prevention of intestinal inflammatory diseases with a bile acid derivative
EP3922264A4 (en) * 2019-02-04 2024-01-10 Riken PHARMACEUTICAL COMPOSITION FOR THE PREVENTION, IMPROVEMENT OR TREATMENT OF SKIN DISEASES
US20220193151A1 (en) * 2019-03-26 2022-06-23 The Children's Medical Center Corporation Therapeutic microbiota for the treatment and/or prevention of dysbiosis
CN109852604A (zh) * 2019-03-28 2019-06-07 贵州大学 高效降解菌核净的单胞属菌固定化菌的制备方法及应用
EP4005578A4 (en) * 2019-07-30 2024-05-01 Kobiolabs, Inc. COMPOSITION AND METHODS FOR PREVENTING, RELIEVING OR TREATING LIVER INJURY
CN112980712A (zh) * 2019-12-14 2021-06-18 山东大学 一种调节高原人群情绪及肠道菌群稳定的微生物组合物及其应用
WO2021137494A1 (ko) * 2020-01-02 2021-07-08 삼육대학교산학협력단 부티리시모나스 속 균주를 유효성분으로 포함하는 당뇨병 예방 또는 치료용 조성물
CN113213984B (zh) * 2020-01-21 2022-09-09 吉林农业大学 一种含死谷芽孢杆菌的生物有机肥及其制备方法和应用
CN111254207A (zh) * 2020-01-22 2020-06-09 郑州大学第一附属医院 用于区别自身免疫性肝炎和健康人群的肠道微生物标志物及其应用
CN111117935A (zh) * 2020-02-10 2020-05-08 农业农村部食物与营养发展研究所 一种抑制肌肉合成的微生物菌剂及其应用
WO2021183701A1 (en) * 2020-03-10 2021-09-16 Federation Bio Inc. Microbial consortia for the treatment of disease
CN111686134A (zh) * 2020-05-15 2020-09-22 上海市第六人民医院东院 一种益生菌组合物及其制备方法和用途
EP4152959A4 (en) * 2020-05-21 2024-07-03 Chan Zuckerberg Biohub Inc HIGH COMPLEXITY SYNTHETIC GUT BACTERIAL COMMUNITIES
CA3186783A1 (en) * 2020-07-30 2022-02-03 John A. KALLASSY Methods and compositions for treating metabolic conditions
KR102269966B1 (ko) 2021-01-12 2021-06-28 주식회사 바이오뱅크힐링 루미노코쿠스 파에시스 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
CN113186132B (zh) * 2021-05-07 2023-05-23 广东丽豪生物农业有限公司 一种适于玉米种植的微生物菌剂和应用
US20240277781A1 (en) * 2021-06-21 2024-08-22 Pendulum Therapeutics, Inc. Compositions Comprising Microbes and Methods of Use and Making Thereof
CN114028938B (zh) * 2021-10-13 2024-03-22 华中农业大学 一株耐高温除氨菌的筛选及应用
CN113789289B (zh) * 2021-11-05 2023-05-16 中山大学附属第三医院粤东医院 评估系统性红斑狼疮患病风险的肠道微生物组合及其检测试剂
CN113881609B (zh) * 2021-11-23 2022-12-23 山东省花生研究所 一株皮特不动杆菌yy-7s及其应用
CN114410554B (zh) * 2022-03-29 2022-06-14 广东省科学院生态环境与土壤研究所 一株具有好氧砷甲基化和挥发功能的噬几丁质菌及其应用
TW202408498A (zh) * 2022-06-30 2024-03-01 南韓商日東製藥股份有限公司 異噁唑衍生物及其鹽之新用途
CN115161406B (zh) * 2022-07-18 2023-04-21 中国农业科学院特产研究所 一种合成菌群的构建方法及其在药用植物高品质栽培中的应用
CN115232772B (zh) * 2022-08-04 2024-05-14 湖北稻花香酒业股份有限公司 Rf1菌及联合科氏梭菌产己酸的方法
WO2024102925A1 (en) * 2022-11-11 2024-05-16 Intercept Pharmaceuticals, Inc. Crystalline forms of a farnesoid x receptor agonist
CN115747111B (zh) * 2022-11-25 2023-12-12 四川大学 一株戊糖片球菌及其应用
CN115976122B (zh) * 2023-01-10 2024-07-23 四川轻化工大学 一种二元混菌产酯发酵体系及其生产酯化液的方法和应用
CN116694535B (zh) * 2023-07-20 2024-08-23 四川大学 一种戊糖乳杆菌w19及其应用
CN117797176B (zh) * 2024-03-01 2024-07-02 南京大学 双孢梭菌在制备治疗非酒精性脂肪性肝病药物中的应用和一种药物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20160665A1 (es) * 2013-05-14 2016-08-07 Intercept Pharmaceuticals Inc Derivados 11-hidroxilo de acidos biliares y conjugados de aminoacidos de los mismos como moduladores del receptor de farnesoid x
US20150258052A1 (en) * 2014-03-13 2015-09-17 Salk Institute For Biological Studies Methods of using fexaramine and agents that increase sympathetic nervous system activity to promote browning of white adipose tissue
US20160095339A1 (en) * 2014-10-01 2016-04-07 Mead Johnson Nutrition Company Nutritional composition for gastrointestinal environment to provide improved microbiome and metabolic profile
CN106083978A (zh) * 2015-04-28 2016-11-09 上海迪诺医药科技有限公司 磺酰基氨基羰基衍生物、其药物组合物及应用

Also Published As

Publication number Publication date
KR20190117687A (ko) 2019-10-16
EP3585405A4 (en) 2020-12-09
CA3053935A1 (en) 2018-08-30
JP2020509001A (ja) 2020-03-26
WO2018156916A3 (en) 2018-10-11
EP3585405A2 (en) 2020-01-01
CN110461337A (zh) 2019-11-15
SG11201907742YA (en) 2019-09-27
AU2018225255A1 (en) 2019-09-05
BR112019017417A2 (pt) 2020-04-07
US20200164005A1 (en) 2020-05-28
WO2018156916A2 (en) 2018-08-30
IL268760A (en) 2019-10-31

Similar Documents

Publication Publication Date Title
MX2019009861A (es) Composiciones farmaceuticas de un derivado de acido biliar y microbioma y usos de las mismas.
PH12018501226A1 (en) Methods for treating huntingtons disease
PH12018502747A1 (en) Boronic acid derivatives and therapeutic uses thereof
MX2018002986A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y sus usos.
NZ739676A (en) Heteroaryl compounds as irak inhibitors and uses thereof
EP4371616A3 (en) Compositions of obeticholic acid and methods of use
SG10201908839QA (en) 2,4-dihydroxy-nicotinamides as apj agonists
MX2016011898A (es) Composiciones de compuestos selenoorganicos y metodos de uso de los mismos.
MX2019015744A (es) Composiciones farmaceuticas.
MX2017014035A (es) Formas solidas novedosas.
MX2020006612A (es) Compuesto que funciona como inhibidor de proteína de bromodominio y composición.
HK1243424A1 (zh) 4'-硫代核苷的新型化合物及其製備方法、藥物組合物和應用
PH12017501539A1 (en) Disacetoxytubulysin h and analogs thereof
PH12019501359A1 (en) Polymorphs
PH12019501362A1 (en) Polymorphs
MY186547A (en) 4?-fluoro-2?-methyl substituted nucleoside derivatives
MX2020002123A (es) Sales de ribociclib y formas en estado sólido de las mismas.
MX2020006596A (es) Hidroxiisoxazolinas y derivados de estos.
PH12017502319A1 (en) Injectable pharmaceutical formulations of lefamulin
MX2020006434A (es) Nuevos compuestos inhibidores del blanco mecanistico de rapamicina (mtor).
NZ757526A (en) Naphthoquinones, their derivatives and uses thereof in methods for the treatment of mitochondrial dysfunction
MX2020000873A (es) Derivados de ácidos biliares marcados isotópicamente.
PH12020550947A1 (en) Polymorphs
MX2018010801A (es) Derivados de acido a-truxilico y composiciones farmaceuticas de los mismos.
MX2020006436A (es) Compuestos inhibidores del blanco mecanistico de rapamicina (mtor).